What Does Wall Street Think About Merck & Co. (MRK)?

Core Insights - Merck & Co., Inc. (NYSE:MRK) is currently viewed as a strong medical stock option, with multiple analysts maintaining a Hold rating on the stock [1][2] - The consensus among analysts is a Moderate Buy, with a median price target of $82.78, indicating an upside potential of 18.39% from current levels [2] Group 1: Analyst Ratings - Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. on September 26 [1] - Roth MKM assigned a Hold rating with a price target of $90 on September 17 [1] - Berenberg Bank downgraded the stock to Hold, reducing the price target from $100 to $90 [2] Group 2: Company Overview - Merck & Co., Inc. is a biopharmaceutical company focused on health solutions for both humans and animals [3] - The Pharmaceutical segment provides vaccines and human health pharmaceutical products, while the Animal Health segment develops and markets veterinary vaccines and pharmaceuticals [3]